Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
AstraZeneca
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Pfizer
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
Hoffmann-La Roche
Astellas Pharma Inc
Quanta Therapeutics
Dana-Farber Cancer Institute
Treeline Biosciences, Inc.
R-Pharm
Pfizer
Incyte Corporation
Chugai Pharmaceutical
Tizona Therapeutics, Inc
Genentech, Inc.
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Pfizer
M.D. Anderson Cancer Center
Boehringer Ingelheim
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Pfizer
Chugai Pharmaceutical
Quanta Therapeutics
Incyte Corporation
City of Hope Medical Center
Bristol-Myers Squibb
Fate Therapeutics
Fate Therapeutics
University of Chicago
C4 Therapeutics, Inc.
Genentech, Inc.
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Quanta Therapeutics
University of Chicago
University of California, San Diego